Product

Prednisolone Ajio

1 form: solution. In force in Georgia: 1 of 1 (human register).

Forms and doses1 of 1 in force in Georgia

Form	Dose	Frequency	Georgia
30 mg/ml, Solution	No label dose in the reference yet	-	Georgia Yes, human In force until 24 Jan 2028 Human (Ministry of Health, RAMA) In the register: პრედნიზოლონი აჯიო 30 მგ/მლ, 1 მლ ამპულა № რ-037192 mis.ge (Ministry of Health register incl. past registrations) Verified on: 16 Oct 2026
Details: pack, label wording, sources, registration Prednisolone Ajio 30 mg/ml, Solution 1 ml ampoule, human medicine vetman assessment vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient. Dog Short-term parenteral prednisolone sodium phosphate as adjunct systemic anti-inflammatory or immunosuppressive treatment for a diagnosed corticosteroid-responsive condition when oral administration is unsuitable 6.2/10 Situational / acceptable vetman assessment Prednisolone Ajio 30 mg/ml, 1 ml ampoule, human medicine Assessed clinical scopeDog · Short-term parenteral prednisolone sodium phosphate as adjunct systemic anti-inflammatory or immunosuppressive treatment for a diagnosed corticosteroid-responsive condition when oral administration is unsuitable · IV,IM Care settingHospital or clinic administration after exact ampoule verification, diagnosis-specific dose selection, aseptic preparation, monitored IV/IM delivery and an early plan to reassess, stop or transition to a better documented formulation vetman score 6.2/10 Situational / acceptable Evidence confidence: Low Georgia: Yes, human · № რ-037192 · Verified on 16 Oct 2026 Off-label use A soluble, rapidly available systemic glucocorticoid presentation that can be a situational clinic bridge when oral treatment is impossible. Its exact human-product use in dogs and cats remains off-label: verify sodium phosphate on the ampoule, derive the dose from an applicable veterinary source, do not substitute depot-acetate dosing, and never delay epinephrine, resuscitation or cause-directed care in an emergency. Regulatory and scientific credibility5.5/10 The exact 30 mg/ml human injection is currently registered in Georgia, and the manufacturer product list confirms prednisolone sodium phosphate and strength. Exhaustive current checks record no exact EU/EEA, GB or US registration; no complete current regulator- or manufacturer-hosted product instruction was located, and there is no dog/cat authorisation for this exact product. Clinical efficacy7.0/10 Prednisolone is an established systemic glucocorticoid, and direct canine work shows rapid, complete conversion of IV prednisolone sodium phosphate to active prednisolone; modern canine IV prednisolone PK/PD data and an authorised veterinary IM solution strengthen biological plausibility. Evidence for clinical outcomes with these exact 30 mg/ml human ampoules remains limited, so benefit depends on a correct diagnosis, dose and cause-directed treatment. Safety and tolerability5.5/10 Brief supervised exposure can be reasonable, but no exact-product canine tolerability study or complete current public official instruction was located. Systemic glucocorticoid risks include infection masking, hyperglycaemia, gastrointestinal injury, fluid/electrolyte effects, HPA suppression and important NSAID interactions; incomplete public excipient and compatibility detail lowers confidence. Clinical practicality7.0/10 The 30 mg/ml ready-to-use 1 ml ampoule is compact, permits rapid clinic-only IV/IM administration and can reduce volume for a larger dog. It is poorly suited to small doses: exact veterinary dosing for this phosphate product is not established, IV access and monitoring are required, and an opened single-use ampoule creates waste when little volume is needed. Full-course cost-effectiveness- Price was not assessed and is excluded from the overall score. Important safety and use flags In anaphylaxis, shock or another immediately life-threatening emergency, this product is not a substitute for epinephrine, airway/oxygen support, IV fluids, vasopressors or cause-directed resuscitation. A glucocorticoid is at most adjunctive and must not delay first-line care. Do not use as a substitute for diagnosis or cause-directed treatment. Systemic prednisolone can suppress fever and inflammation while an uncontrolled infection, neoplasia, endocrine disorder or other underlying disease progresses. Avoid concurrent NSAIDs and use an indication-appropriate washout when switching; the combination materially increases gastrointestinal ulceration, perforation and bleeding risk. Avoid use with active gastrointestinal ulceration. Avoid or use only after explicit benefit-risk assessment with uncontrolled infection, diabetes mellitus, hyperadrenocorticism, uncontrolled hypertension, glaucoma, osteoporosis, important cardiac/renal dysfunction, corneal ulceration or major thrombotic risk. Do not administer modified-live vaccines during immunosuppressive treatment. Review vaccination timing and expected immune response before and after systemic glucocorticoid exposure. Confirm prednisolone sodium phosphate, concentration, route and expiry on the exact ampoule. Do not substitute a dose from prednisolone acetate depot suspension or another soluble ester; these formulations have different release and exposure profiles. Administer only in a clinic with aseptic technique, accurate low-volume measurement and route-appropriate monitoring. Establish patency before IV use, give at a controlled rate and observe cardiovascular, respiratory, neurologic and injection-site response. No exact-product veterinary dose is established. Select dose, interval and duration from an applicable veterinary source for the diagnosed condition and soluble formulation; reassess response early and avoid automatic repeat dosing. With repeated or extended exposure, monitor weight, appetite, water intake/urination, blood pressure, infection signs, CBC, chemistry, glucose and urine as risk warrants. Taper sustained supraphysiologic treatment rather than stopping abruptly. Safety of these exact human ampoules in breeding, pregnant, lactating, neonatal or growing dogs and cats is not established. Use only after a documented veterinary benefit-risk assessment and consider a better characterised alternative. Assessment sources Agio phosphate product record2026 Veterinary injection UPD2026 VMD SPC 20232023 MSD corticosteroids2026 MSD airway glucocorticoids2026 Canine IV prednisolone phosphate PK1977 Canine IV prednisolone PK/PD2021 Feline oral prednisolone PK2013 Canine glucocorticoid AEs2020 RECOVER anaphylaxis guideline2026 Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised. Cat Short-term parenteral prednisolone sodium phosphate as adjunct systemic anti-inflammatory or immunosuppressive treatment for a diagnosed corticosteroid-responsive condition when oral administration is unsuitable 5.6/10 Weak evidence support vetman assessment Prednisolone Ajio 30 mg/ml, 1 ml ampoule, human medicine Assessed clinical scopeCat · Short-term parenteral prednisolone sodium phosphate as adjunct systemic anti-inflammatory or immunosuppressive treatment for a diagnosed corticosteroid-responsive condition when oral administration is unsuitable · IV,IM Care settingHospital or clinic administration after exact ampoule verification, diagnosis-specific dose selection, aseptic preparation, monitored IV/IM delivery and an early plan to reassess, stop or transition to a better documented formulation vetman score 5.6/10 Weak evidence support Evidence confidence: Low Georgia: Yes, human · № რ-037192 · Verified on 16 Oct 2026 Off-label use A soluble, rapidly available systemic glucocorticoid presentation that can be a situational clinic bridge when oral treatment is impossible. Its exact human-product use in dogs and cats remains off-label: verify sodium phosphate on the ampoule, derive the dose from an applicable veterinary source, do not substitute depot-acetate dosing, and never delay epinephrine, resuscitation or cause-directed care in an emergency. Regulatory and scientific credibility5.5/10 The exact 30 mg/ml human injection is currently registered in Georgia, and the manufacturer product list confirms prednisolone sodium phosphate and strength. Exhaustive current checks record no exact EU/EEA, GB or US registration; no complete current regulator- or manufacturer-hosted product instruction was located, and there is no dog/cat authorisation for this exact product. Clinical efficacy6.5/10 Prednisolone has an established systemic role in cats, but evidence for IV/IM sodium phosphate in this species is mainly transferred from feline prednisolone disposition, general glucocorticoid practice and canine parenteral data. The soluble phosphate should not be treated as interchangeable with authorised prednisolone acetate depot suspension, and no exact-product feline outcome study was located. Safety and tolerability5.0/10 No exact-product feline tolerability study or complete current public official instruction was located. Cats remain vulnerable to infection, diabetes, gastrointestinal injury, fluid/cardiac effects and HPA suppression, while indirect route evidence, small injection volumes and incomplete public excipient/compatibility detail narrow the safety margin. Clinical practicality5.5/10 A 30 mg/ml ampoule produces very small volumes for many cats, making accurate measurement difficult without an appropriately graduated low-volume syringe and an independently justified dose. IV access/restraint and monitoring add burden, and most of the 1 ml ampoule may be discarded; it is a clinic rescue/bridge presentation, not a convenient routine feline formulation. Full-course cost-effectiveness- Price was not assessed and is excluded from the overall score. Important safety and use flags In anaphylaxis, shock or another immediately life-threatening emergency, this product is not a substitute for epinephrine, airway/oxygen support, IV fluids, vasopressors or cause-directed resuscitation. A glucocorticoid is at most adjunctive and must not delay first-line care. Do not use as a substitute for diagnosis or cause-directed treatment. Systemic prednisolone can suppress fever and inflammation while an uncontrolled infection, neoplasia, endocrine disorder or other underlying disease progresses. Avoid concurrent NSAIDs and use an indication-appropriate washout when switching; the combination materially increases gastrointestinal ulceration, perforation and bleeding risk. Avoid use with active gastrointestinal ulceration. Avoid or use only after explicit benefit-risk assessment with uncontrolled infection, diabetes mellitus, hyperadrenocorticism, uncontrolled hypertension, glaucoma, osteoporosis, important cardiac/renal dysfunction, corneal ulceration or major thrombotic risk. Do not administer modified-live vaccines during immunosuppressive treatment. Review vaccination timing and expected immune response before and after systemic glucocorticoid exposure. Confirm prednisolone sodium phosphate, concentration, route and expiry on the exact ampoule. Do not substitute a dose from prednisolone acetate depot suspension or another soluble ester; these formulations have different release and exposure profiles. Administer only in a clinic with aseptic technique, accurate low-volume measurement and route-appropriate monitoring. Establish patency before IV use, give at a controlled rate and observe cardiovascular, respiratory, neurologic and injection-site response. No exact-product veterinary dose is established. Select dose, interval and duration from an applicable veterinary source for the diagnosed condition and soluble formulation; reassess response early and avoid automatic repeat dosing. With repeated or extended exposure, monitor weight, appetite, water intake/urination, blood pressure, infection signs, CBC, chemistry, glucose and urine as risk warrants. Taper sustained supraphysiologic treatment rather than stopping abruptly. Safety of these exact human ampoules in breeding, pregnant, lactating, neonatal or growing dogs and cats is not established. Use only after a documented veterinary benefit-risk assessment and consider a better characterised alternative. Assessment sources Agio phosphate product record2026 Veterinary injection UPD2026 VMD SPC 20232023 MSD corticosteroids2026 MSD airway glucocorticoids2026 Canine IV prednisolone phosphate PK1977 Canine IV prednisolone PK/PD2021 Feline oral prednisolone PK2013 Canine glucocorticoid AEs2020 RECOVER anaphylaxis guideline2026 Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised. Composition / strength Prednisolone30 mg/ml Formulation Type Solution Administration route Intravenous, Intramuscular Manufacturer Ajio Pharmaceuticals Registration Georgia Yes, human In force until 24 Jan 2028 Human (Ministry of Health, RAMA) In the register: პრედნიზოლონი აჯიო 30 მგ/მლ, 1 მლ ამპულა № რ-037192 mis.ge (Ministry of Health register incl. past registrations) Verified on: 16 Oct 2026 EU No EMA Article 57 database (all medicines authorised in the EU/EEA), 09.10.2026 Verified on: 16 Oct 2026 UK No MHRA Products (UK) Verified on: 16 Oct 2026 US No Drugs@FDA (openFDA) Verified on: 16 Oct 2026 Controlled in Georgia No Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n. matsne.gov.ge Verified on: 16 Oct 2026

Active substance doses, with sources

Each dose comes with its source. Check the label of the product you use.

Active substance Prednisolone

Dose calculatorCalculates the active-substance amount; it is not a prescription.

PatientSpecies and weight will be filled in automatically in other calculators.

Species Weight (kg)

Indication

Selected dose

Product presentation

Dose	Species	Indication	Route	Frequency	Source
0.1–2 mg/kg	Dog, Cat	Inflammation	By mouth	once daily	VMD SPC 2026 Official product label (SPC), VMD, UK Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there. Prednicare 5 mg Tablets - Summary of Product Characteristics UK Veterinary Medicines Directorate, Product Information Database, 2026 Open the source ↗
0.5–4 mg/kg	Dog, Cat	Immune-Mediated Disease	By mouth	once daily	VMD SPC 2025 Official product label (SPC), VMD, UK Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there. Prednicortone 5 mg Tablets for Dogs and Cats - Summary of Product Characteristics UK Veterinary Medicines Directorate, Product Information Database, 2025 Open the source ↗
0.5–1 mg/kg	Dog, Cat	Inflammation	Intramuscular	Single dose	VMD SPC 2023 Official product label (SPC), VMD, UK Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there. Cortico Veyxin 10 mg/ml Suspension for Injection - Summary of Product Characteristics UK Veterinary Medicines Directorate, Product Information Database, 2023 Open the source ↗

Known Contraindications

Critical
An uncontrolled viral, fungal, or parasitic infection is an absolute contraindication. The parasitic-infection restriction is specified on the Prednicare label.
Critical
Diabetes mellitus is an absolute contraindication on the Prednicare and Prednicortone labels.

Sources: Product label
Critical
Hyperadrenocorticism is an absolute contraindication on the Prednicare and Prednicortone labels.

Sources: Product label
Critical
Osteoporosis is an absolute contraindication on the Prednicare and Prednicortone labels.

Sources: Product label
Critical
Corneal ulceration is an absolute contraindication on the Prednicare and Prednicortone labels.

Sources: Product label
Critical
Glaucoma is an absolute contraindication on the Prednicare and Prednicortone labels.

Sources: Product label
Critical
Hypersensitivity to prednisolone or any excipient is an absolute contraindication on the Prednicare and Prednicortone labels.

Sources: Product label
Critical
Burn injury is listed as a contraindication on the Prednicortone label but not on the other two reviewed labels.

Sources: Product label
Critical
Cataract is listed as a contraindication on the Cortico Veyxin label.

Sources: Product label
Critical
Hypocalcaemia is listed as a contraindication on the Cortico Veyxin label.

Sources: Product label
Critical
Hypertension is listed as a contraindication on the Cortico Veyxin label.

Sources: Product label
Critical
Pancreatitis is listed as a contraindication on the Cortico Veyxin label.

Sources: Product label
Critical
A poorly healing wound or fracture is listed as a contraindication on the Cortico Veyxin label.

Sources: Product label
Critical
General immunodeficiency is listed as a contraindication on the Cortico Veyxin label.

Sources: Product label
Critical
Gastrointestinal ulceration is an absolute contraindication on all three reviewed labels. Concomitant corticosteroid and NSAID treatment further increases the risk of ulceration; see the interaction warnings.

Sources: Product label
Critical
cardiac or renal dysfunction

Sources: Product label
Critical
Severe renal impairment is an absolute contraindication on the Prednicare label.

Sources: Product label
Critical
Do not use during pregnancy. Some corticosteroid products specify this restriction for the final third of gestation.
Warning
Use in growing animals carries a risk of growth retardation, suppression of bone growth, and damage to the bone matrix.
Warning
Do not use with a live attenuated vaccine because corticosteroids suppress the immune response to vaccination. The Prednicortone label also prohibits use within 2 weeks after vaccination.
Warning
very rare

Known Drug Interactions

Contraindicated Meloxicam + Prednisolone
Concomitant use of corticosteroids and non-steroidal anti-inflammatory drugs can worsen gastrointestinal ulceration.

Recommendation: Do not administer together. Observe an appropriate washout period when switching and monitor for melena, vomiting, and reduced appetite.

Sources: Product label
Contraindicated Robenacoxib + Prednisolone
Do not give robenacoxib together with other non-steroidal anti-inflammatory drugs or glucocorticoids because adverse gastrointestinal and renal effects may increase.

Recommendation: Do not use these drugs together. Allow a treatment-free interval of at least 24 hours after the previous anti-inflammatory drug, extending it when required by that drug’s pharmacokinetics.
Major warning Prednisolone + Insulin glargine
Glucocorticoids, progestogens, and certain endocrinopathies can have an antagonistic effect on insulin activity. Glucocorticoid and progestogen use should be avoided.

Recommendation: Avoid the combination. If the glucocorticoid cannot be discontinued within 2 weeks, the insulin dose may need to be increased; monitor glycaemia.

Sources: FDA · AAHA
Major warning Prednisolone + Insulin human
Glucocorticoids, progestogens, and certain endocrinopathies can have an antagonistic effect on insulin activity. Glucocorticoid and progestogen use should be avoided.

Recommendation: Avoid the combination. If the glucocorticoid cannot be discontinued within 2 weeks, the insulin dose may need to be increased; monitor glycaemia.

Sources: FDA · AAHA
Major warning Furosemide + Prednisolone
Concurrent use with drugs affecting electrolyte balance (corticosteroids, other diuretics, amphotericin B, cardiac glycosides) requires careful monitoring.

Recommendation: Monitor electrolytes, particularly potassium. Check periodically during prolonged combination therapy.

Sources: VMD SPC · VMD
Major warning Carprofen + Prednisolone
Do not give other non-steroidal anti-inflammatory drugs or glucocorticoids concurrently with carprofen or within 24 hours of treatment because gastrointestinal ulceration or perforation may occur.

Recommendation: Consider appropriate washout times when switching from one NSAID to another or when switching from corticosteroid use to NSAID use.

Sources: FDA

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Prednisolone Ajio

Forms and doses1 of 1 in force in Georgia